The one randomised trial that combined an incretin with supervised exercise

The recommendation to train while losing weight is not controversial and this publication endorses reporting it. What deserves scrutiny is the mechanism usually offered alongside it. Resistance training during a substantial energy deficit does not reliably build muscle; the deficit is the binding constraint and no amount of load overcomes a large one. What it reliably does is attenuate the loss and, more consistently still, preserve strength and physical function even where mass declines. Those are different claims with different evidence behind them, and only the second is well supported.

What the semaglutide DXA substudy measured

In the STEP 1 trial of once-weekly semaglutide 2.4 mg in adults with overweight or obesity without diabetes, mean weight reduction at sixty-eight weeks was approximately 14.9 per cent against 2.4 per cent on placebo.¹ A body-composition substudy conducted at a subset of sites scanned approximately one hundred and forty participants by dual-energy X-ray absorptiometry at baseline and at week sixty-eight.

The substudy reported a reduction in total fat mass of roughly nineteen per cent in the semaglutide group, a smaller absolute reduction in lean body mass, and consequently an increase in the proportion of total body mass that was lean — from approximately fifty-seven per cent at baseline to approximately sixty-one per cent at week sixty-eight. Regional visceral fat mass fell proportionally more than total fat mass, which is the metabolically favourable direction.

Converted into the currency people argue in, roughly a third to two-fifths of the total mass lost in that substudy was lean tissue by the DXA definition. That is unremarkable against the dietary weight-loss literature. It is also a group mean from one hundred and forty people, reported at a single follow-up point, with no strength or function measurement alongside it.

What the systematic reviews support

Two syntheses are worth separating. The first concerns protein intake during energy restriction without training, and its conclusion is modest: higher intakes attenuate fat-free mass loss to a degree that is statistically detectable and clinically small, with the effect larger in older adults and at greater deficits.² The second concerns protein plus resistance training, where the effect is larger and more consistent, and where the protein and the training are difficult to separate because they interact.

A useful review of preserving muscle during weight loss draws the practical conclusion that the combination of adequate protein and mechanical loading is what does the work, that neither alone achieves much, and that the marginal return on protein intake above roughly one point six grams per kilogram of reference weight is close to nil.³ That last point is the one most often dropped: the dose-response curve flattens, and intakes of three grams per kilogram — which appear in consumer advice with some regularity — have no supporting evidence and a real opportunity cost in an appetite that only accommodates so much food.

None of these syntheses included a participant taking an incretin. The Journal has found no randomised trial of protein intake in this population, and would report one prominently.

The one trial that combined an agonist with supervised exercise

A Danish randomised trial remains the only controlled test of the obvious question. After an eight-week low-energy diet producing approximately thirteen kilograms of weight loss, participants were randomised for one year to supervised exercise alone, liraglutide 3.0 mg alone, both combined, or placebo.⁴ The combination arm achieved the largest weight reduction and, more relevantly here, the most favourable composition outcome: body fat percentage fell roughly twice as much in the combination group as in either single-intervention group, and the exercise arms preserved lean mass better than the drug-alone arm.

Three qualifications belong with that result. The exercise was supervised and substantial — two group sessions and two individual sessions weekly, with a vigorous-intensity target — which is not what most people mean by adding exercise. The agent was liraglutide at 3.0 mg daily, producing considerably less weight loss than the current agents, so whether the interaction scales to a twenty per cent reduction is unknown. And the trial began after weight had already been lost, so it is a maintenance study rather than an induction study.

With those stated, it is the best evidence in the field and it points in the direction the general advice already points.

What the older-adult trials found

The closest analogue to rapid weight loss in an older, heavier population predates this drug class entirely. In a randomised trial of adults aged sixty-five and over with obesity, assigned to diet, exercise, both or a control condition for a year, the combination produced the largest improvement in physical function, and the exercise component attenuated the loss of lean mass and of bone mineral density that diet alone caused.⁵ Diet alone improved function too — carrying less mass helps — but by less, and at a measurable skeletal cost.

That trial is the template for how the question should be asked in this class: randomise the co-intervention, measure function as a primary endpoint, measure bone, and follow for long enough for the skeleton to respond. Its population, older and heavier and losing weight quickly, resembles a large share of current incretin users far more closely than the young resistance-trained cohorts from which most consumer advice descends.

The Journal cites it frequently for that reason and notes the obvious limitation: the weight loss achieved was roughly a tenth of body mass over a year, which is half or less of what the current agents produce. Whether the protective effect of training holds at twice the rate of loss is not established.

The prescription survives scrutiny; the reasoning often does not

Two claims are routinely bundled together and only one is well supported. The weaker claim is that resistance training during pharmacological weight loss builds or maintains muscle mass. In a substantial energy deficit, training generally attenuates the loss rather than preventing it, and net accrual is unusual outside of untrained beginners and the specific controlled-feeding conditions of the trials cited earlier. The stronger claim is that training preserves strength and physical function even where mass declines, which is consistently observed and is mechanistically sensible: a large part of early strength change is neural rather than structural.

The distinction has practical consequences. Somebody training hard, eating well, and watching their DXA appendicular lean mass fall by two kilograms across nine months has not failed at anything, and may be measurably stronger than at baseline. If the expectation set for them was mass preservation, they will read a normal outcome as a failure and may respond by eating more or training in ways that suit the metric rather than the goal.

The Journal reports the training recommendation and reports what it is expected to achieve, which is function first and mass second.

Sarcopenia is a diagnosis, not a synonym

The word sarcopenia has migrated from clinical medicine into consumer discussion of this drug class and lost its definition in transit. In the working definitions used by the European and Asian consensus groups, sarcopenia requires low muscle strength, with low muscle quantity or quality confirming it and poor physical performance indicating severity. Strength is the entry criterion. Reduced lean mass on a scan, in the absence of measured weakness, does not meet any published definition of sarcopenia.

This matters because the borrowed term imports a prognosis. Sarcopenia in its clinical sense is associated with falls, fractures, hospitalisation and mortality, and those associations were established in older adults with measured weakness, frequently in the context of illness or immobility. Applying the label to a forty-two-year-old whose DXA appendicular lean mass has fallen by one and a half kilograms while their strength has increased is not a cautious extrapolation; it is a category error with a frightening prognosis attached.

The related term sarcopenic obesity has the same problem in a more acute form, since it requires both criteria to be met and is frequently used to mean nothing more than a low lean fraction. The Journal uses both terms only in their defined sense and asks correspondents who use them to say which criteria they mean.

How the Journal reports a body-composition figure

Four things accompany every composition number in these pages. The instrument, because DXA, magnetic resonance, bioimpedance and creatine dilution are not interchangeable and the choice frequently determines the sign of the result. The sample size of the substudy rather than of the parent trial, because the parent trial size is irrelevant to the composition finding and quoting it is misleading. The definition used — total lean mass, lean soft tissue, appendicular lean mass or fat-free mass — because these differ by several kilograms in the same person. And whether the figure is a proportion of body mass or an absolute quantity.

Where a source omits any of the four, we say so rather than guessing, and where we have had to convert between definitions we show the conversion. This is more cumbersome than the alternative and it is the only way we have found to write about this subject without producing sentences that are technically true and practically misleading.

Readers who find a figure in these pages that lacks its instrument and its sample size have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

What the testing services can and cannot tell you here

A category confusion arrives in the Journal postbag with some regularity, and it is worth addressing directly. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse the contents of a vial. They report chromatographic purity, identity by mass, sometimes peptide content, and in the case of the verification services, what they were able to establish about a supplier. None of them measures anything about a person.

A certificate stating 98.7 per cent purity for a batch supplied by WWB, SSA or KP is silent on that customer’s body composition, and a low-purity result does not explain a disappointing DXA scan. The two questions are answered by different instruments in different buildings, and conflating them produces a particular kind of dead end in which somebody spends several hundred pounds on analytical testing to investigate a clinical question.

The reverse confusion also occurs: a satisfactory laboratory panel or a favourable body-composition scan is offered as evidence that a vial contained what its label claimed. It is not evidence of that either. Compounds sold for research use only are not approved for human use, and nothing in this section should be read as advice about using them.

The Journal position on body composition is narrower than either camp would like. The drugs produce weight loss whose composition is, on the available imaging, at least as favourable as dietary weight loss and probably slightly better. The absolute lean-mass reduction accompanying a twenty per cent weight loss is nevertheless substantial, is unmeasured in functional terms, and is a reasonable thing for an older or already frail person to want managed. Both of those sentences are true and the argument has largely consisted of people insisting on one of them.